|
|
 |
|
Viewing report
|
|
|
|
Investment and Business Trends in Biotechnology: The Year 2004 in Review
Decision Resources, Inc, March 2005, Pages: 17
Marking renewed confidence in the biotechnology sector, in 2004 the biotechnology industry experienced an upswing in initial public offerings (IPOs), private equity financings, and pharmaceutical corporate partnerships for lead compounds. Despite this reinvigorated activity, pharmaceutical companies and investors are proceeding in a battle-tempered mode of cautious optimism. The deals and alliances of 2004 highlight growing trends that will impact both the pharmaceutical and biotechnology industries in the near future.
In this report, we discuss major trends in biotechnology financing and dealmaking in 2004 and describe selected corporate deals and alliances among biotechnology and pharmaceutical companies. In addition, we examine the dynamics of the relationship between these industries, and discuss how biotech companies can successfully adapt to these dynamics.
Business Implications
- In 2004, the biotechnology industry experienced an upswing in initial public offerings (IPOs), private equity financings, and corporate partnerships for lead compounds. More than 50 biotechnology companies completed IPOs worldwide, with 28 companies going public in the United States. Investments and dealmaking favored companies with products in clinical development and highly validated leads and targets.
- The birth of venture capital (VC) mega-funds affected biotechnology private equity financing considerably. Because VC mega-funds need to make large investments, they seek out lower-risk deals. VCs in 2004 principally invested in companies with pipelines of late-stage clinical candidates and with major corporate partnerships. This trend is creating a financing gap for early-stage companies.
- In 2004, pharmaceutical companies strongly favored biotech companies with drugs in late-stage clinical trials or with highly validated preclinical candidates. Alliances reflected a demand for higher degrees of target validation, a shift toward lead identification, a preference for technologies likely to yield drug candidates in the near term, and a greater demand for biotechnology companies to share risk.
- Biotech companies that incorporated change, forward integration, and adaptation into their business models have attained higher values than those that remained married to their initial core technologies. Most companies that continued to concentrate on original core technologies have remained small-cap companies. The ability and will to adapt to the pharmaceutical industry’s changing needs and tastes is critical for success.
- As the number of biotechnology lead compounds proceeding through late-stage development increases, the industry must brace for the inevitable wave of upcoming failures in late-stage clinical trials due to typical compound attrition. This scenario may shift future corporate partnerships and investments back toward platform technologies that aid in the selection of better drug targets, pathways, and leads.
|
|
|
|
